Labiotech.eu

News and Trends 1 Jul 2015

Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?

Adocia and Eli Lilly completed an impressive Phase Ib clinical trial evaluating BioChaperone Lispro, a treatment designed to accelerate insulin absorption. The study aimed to compare BioChaperone Lispro to Lilly’s Humalog in type 1 diabetes patients, the former being much more effective. Humalog, Lilly’s blockbuster, is about to be ousted by Adocia’s insulin absorption accelerator. BioChaperone Lispro […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jul 2015

Two of Alexion’s rare-disease drugs get the thumbs up from the EU

The European Medicines Agency (EMA) is about to approve a couple of rare diseases drugs developed by Alexion. The two enzymes, Strensiq and Kanuma, received positive feedback from the EMA’s Committee for Medicinal Products for Human Use, which normally leads to the approval of the drug. The Committee for Medicinal Products for Human Use has […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jul 2015

mRNA Therapies: CureVac Outperformed the Money Magnet Moderna

Everybody has already heard about Boston-based Moderna Therapeutics, the most highly valued venture-backed private Biotech, but CureVac, its German competitor, remains much more understated. This could rapidly change as CureVac just demonstrated that its technology beats Moderna’s. mRNA technologies could theoretically disrupt the whole drug industry. Imagine that you can directly inject mRNA into patients to make them produce their own therapeutic proteins. Unfortunately, […]

July 1, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 1 Jul 2015

Green light for one of the largest clinical trials in Immunotherapy

In a period, where uncountable big pharmas and biotechs are struggling to get the largest piece of the immunotherapy cake, an unexpected player has arrived. TxCell, a French biotech, received an option to extend its current phase IIb study from EU to US, a stage that lots of immunotherapy experts would like to reach. TxCell was founded fourteen years […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Jun 2015

Stallergenes and Greer to create the World Leader in Allergy Immunotherapy

A few months ago, we were talking about the refusal of Stallergenes’ minority shareholders to merge with Greer laboratories, another competitor within the field of allergy treatment. Finally, Stallergenes shareholders accepted, and both companies are going to create the world leader in allergy immunotherapy. After the sale of Serono to Merck back in 2007, the magnate Ernesto Bertarelli started its […]

June 30, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2015

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Transgene, the oldest French Biotech company announced just yesterday that it will cut 120 jobs on its current 300 employees. The company will shut down its manufacturing facility in order to focus on the Research and Development of its therapeutic vaccine candidates. Wise move or final last words? Back in 1976, Robert Swanson and Herbert Boyer founded […]

June 30, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2015

Qiagen vs. Illumina, the next Big Fight in Next-gen Sequencing

Next-gen sequencing is a revolution. San Diego-based Illumina owns most of the market but German giant Qiagen is prepared to disrupt this fact by stepping in massively by the end of the year. The fight has only begun. Imagine you could sequence your genome to discover the disease you may have in the future. What if I told you, […]

June 30, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 29 Jun 2015

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Actelion has created a new start-up in the field of synthetic carbohydrate vaccines, together with the Max Planck Society. Actelion has made a funding commitment of up to €30M to back the new company, Vaxxilon. Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and Interfaces discovered the first preclinical […]

June 29, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 29 Jun 2015

Novartis pays €625M for Spinifex’s chronic pain treatment

[Update 06.30.2015] According to an email sent to FierceBiotech by Spinifex’s CEO Tom McCarthy, Novartis could pay an additional $500m (approximately €445m) of future milestones to Spinifex’s shareholders. Spinifex Pharmaceuticals, a US-Australian biotechnology company has just been bought by Novartis. With this acquisition, the Swiss giant aims to control the development of EMA401, a new treatment for […]

June 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 29 Jun 2015

6 Things the Digital Revolution already Disrupted in the Biotech Industry

2 weeks ago, I was at NOAH15 in Berlin, one of the biggest European events on Digital, gathering key opinion leaders such as Eric Schmidt from Google or Ariana Huffington, founder of the Huffington Post. They all talked about the impact of the recent digital wave, internet and the post-pc area in different industries. Biotech […]

June 29, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 28 Jun 2015

Google and big names helped Oxford Sciences Innovation to raise €457M

Oxford Sciences Innovation has completed the second close of its fundraising, raising an additional €157.3M (£110M) and bringing the total amount raised to €457.6M (£320M). This second close included some well-known investors such as Google Ventures and Charles Dunstone. Being backed by one of the best-recognized institutions in the world has its advantages. Oxford University […]

June 28, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Jun 2015

AstraZeneca’s senior managers are abandoning ship

In just a couple of weeks, AstraZeneca has seen two of its chiefs leave their position to run two smaller biotechs. James Ward-Lilley made his exist from Astra to become CEO of Vectura, just a few days after Briggs Morrison abruptly left to also become CEO of Syndax. The rich also cry, said the telenovela and […]

June 25, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?

Two of Alexion’s rare-disease drugs get the thumbs up from the EU

mRNA Therapies: CureVac Outperformed the Money Magnet Moderna

Green light for one of the largest clinical trials in Immunotherapy

Stallergenes and Greer to create the World Leader in Allergy Immunotherapy

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Qiagen vs. Illumina, the next Big Fight in Next-gen Sequencing

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Novartis pays €625M for Spinifex’s chronic pain treatment

6 Things the Digital Revolution already Disrupted in the Biotech Industry

Google and big names helped Oxford Sciences Innovation to raise €457M

AstraZeneca’s senior managers are abandoning ship

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!